๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Recurrent Hepatocellular Carcinoma

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC NCT06609876NA1 site๐Ÿ“ Beijing Sun Yat-sen University ยท Tests: Thermal ablation, Donafenib HOPE Against Cancer Recurrence in HCC NCT06717919Phase 437 sites๐Ÿ“ New York๐Ÿ“ Cleveland๐Ÿ“ Innsbruck Philipp Dutkowski ยท Tests: Hypothermic oxygenated perfusion, Conventional cold storage Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site๐Ÿ“ Portland OHSU Knight Cancer Institute ยท Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence NCT06644937Phase 2, Phase 31 site๐Ÿ“ Guangzhou Zhujiang Hospital ยท Tests: TACE combined with Acoradine HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence NCT06812039Phase 23 sites๐Ÿ“ Fuzhou๐Ÿ“ Shanghai๐Ÿ“ Tianjin Fudan University ยท Tests: HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer NCT05323201Phase 1, Phase 21 site๐Ÿ“ Xuzhou The Affiliated Hospital of Xuzhou Medical University ยท Tests: fhB7H3.CAR-Ts, Fludarabine, Cyclophosphamide Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma NCT06254248Phase 210 sites๐Ÿ“ Clichy๐Ÿ“ Crรฉteil๐Ÿ“ Lille Assistance Publique - Hรดpitaux de Paris ยท Tests: Systemic therapy Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo NCT07239245Phase 24 sites๐Ÿ“ Beijing๐Ÿ“ Zhengzhou๐Ÿ“ Shenyang Cancer Institute and Hospital, Chinese Academy of Medical Sโ€ฆ ยท Tests: Atezolizumab, Bevacizumab, Transarterial chemoembolization (TACE) Recurrent Liver Cancer: Reconceptualization and Reevaluation NCT06430983n/a1 site๐Ÿ“ Nanjing Nanjing Medical University Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab NCT06498622Phase 22 sites๐Ÿ“ Fuyang๐Ÿ“ Hefei Anhui Provincial Hospital ยท Tests: Donafenib + Envafolimab The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma NCT06609850NA1 site๐Ÿ“ Beijing Sun Yat-sen University ยท Tests: TACE, Ablation, Lenvatinb Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention NCT07282184Phase 1, Phase 21 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: Neoadjuvant HAIC + Lenvatinib + PD-1 Inhibitor, Curative Liver Resection, Multimodal AI Risk Stratification The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) NCT07064681n/a1 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Surgery with and without the aid of Indocyanine Green (ICG) A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection NCT05489289Phase 31 site๐Ÿ“ Shanghai Akeso ยท Tests: AK104, placebo HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma NCT04499833NA1 site๐Ÿ“ Lisbon Centro Hospitalar de Lisboa Central ยท Tests: liver transplant Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance NCT07636148n/a3 sites๐Ÿ“ Lyon๐Ÿ“ Crรฉteil๐Ÿ“ Leiden Mark C Burgmans, MD PhD A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma NCT05417932Phase 1, Phase 26 sites๐Ÿ“ New York๐Ÿ“ New York๐Ÿ“ Hong Kong SCG Cell Therapy Pte. Ltd. ยท Tests: SCG101 Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors NCT07337460Phase 21 site๐Ÿ“ Yangzhou Northern Jiangsu People's Hospital ยท Tests: Icaritin Soft Capsules and mFOLFOX ๏ผšOxaliplatin,leucovorin calcium,5-fluorouracil A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk NCT06930573Phase 41 site๐Ÿ“ Zhengzhou The First Affiliated Hospital of Zhengzhou University ยท Tests: AK112 Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection NCT06454578Phase 21 site๐Ÿ“ Jinan Qilu Hospital of Shandong University ยท Tests: Adebrelimab + Apatinib Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model NCT06420440Phase 22 sites๐Ÿ“ Xiangyang๐Ÿ“ Jinan Chen Xiaoping ยท Tests: Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab, Liver resection, Tislelizumab Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA NCT05375370NA1 site๐Ÿ“ Rouen University Hospital, Rouen ยท Tests: circulating tumor DNA dosage Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery NCT06762782Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: Postoperative adjuvant lenvatinib, Supportive care measures Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates NCT05276037n/a6 sites๐Ÿ“ Antwerp๐Ÿ“ Brussels๐Ÿ“ Ghent University of Liege ยท Tests: Liver transplantation Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation NCT06236568NA1 site๐Ÿ“ Modena Azienda Ospedaliero-Universitaria di Modena ยท Tests: D-HOPE machine perfusion, Liver transplantation Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA NCT06157060n/a7 sites๐Ÿ“ Foshan๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Zhujiang Hospital ยท Tests: circulating tumor DNA AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR) NCT07062380n/a1 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: Curative liver resection, Real-world multimodal therapy Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3 NCT05738980NA1 site๐Ÿ“ Beijing Beijing Hospital ยท Tests: Autologous RAK cells TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors NCT07242417EARLY Phase 12 sites๐Ÿ“ Beijing๐Ÿ“ Beijing Beijing GoBroad Hospital ยท Tests: TC-G203 cells treatment Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC NCT05596630NA1 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Stereotactic body radiation therapy
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy